Who is sponsoring NCT07058233?

NCT07058233 is sponsored by RSUP Persahabatan.

What drugs are being tested in NCT07058233?

Interventions in NCT07058233: Oral nutritional supplementation.

What condition does NCT07058233 study?

NCT07058233 studies Tuberculosis Multi Drug Resistant Active, Rifampin-Resistant Pulmonary Tuberculosis, Pre-xdr tb.

Is NCT07058233 still recruiting?

NCT07058233 is currently completed. Last updated 10 July 2025.

Last reviewed 2025-07-10 · How we verify

NCT07058233

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Nutritional Supplementation and Weight Changes During Therapy in Malnourished Patients With Resistant Tuberculosis: A Clinical Trial

Completed NA Last updated 10 July 2025

What this trial tests

NA trial testing Oral nutritional supplementation in Tuberculosis Multi Drug Resistant Active in 70 participants. Completed in 30 December 2022.

Timeline

1 April 2022

Primary endpoint
30 December 2022

30 December 2022

Quick facts

Lead sponsor	RSUP Persahabatan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	70
Start date	1 April 2022
Primary completion	30 December 2022
Estimated completion	30 December 2022
Sites	1 location across Indonesia

Drugs / interventions tested

Oral nutritional supplementation

Conditions studied

Tuberculosis Multi Drug Resistant Active — all drugs for Tuberculosis Multi Drug Resistant Active →
Rifampin-Resistant Pulmonary Tuberculosis — all drugs for Rifampin-Resistant Pulmonary Tuberculosis →
Pre-xdr tb — all drugs for Pre-xdr tb →

Sponsor

RSUP Persahabatan

Who can join

Adults 15 to 65, any sex, with Tuberculosis Multi Drug Resistant Active or Rifampin-Resistant Pulmonary Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tuberculosis increases energy demands and protein breakdown, leading to muscle wasting. Malnutrition and minimal weight gain less than 5% in first two months predict treatment failure. Malnutrition is defined as weight loss more than 5% in three months and Body Mass Index (BMI) ≤ 20 kg/m². This study assesses weight changes with high-energy, high-protein oral nutritional supplementation (ONS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Oral nutritional supplementation

Trials testing the same drug.

NCT07210658 — Acceptability, Gastrointestinal Tolerance, Compliance and Palatability Study. · NA · recruiting

Other RSUP Persahabatan trials

Trials by the same sponsor.

NCT07397130 — Inspiratory Muscle Pressure and Diaphragmatic Strength in Women With Long COVID-19: A Pressure Biofeedback-Guided Traini · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07058233 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RSUP Persahabatan
Last refreshed: 10 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07058233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing